Rhinocerebral Mucormycosis Treated with Posaconazole: A Case Report

被引：7

作者：

Demiroglu, Yusuf Ziya ^{[1
]}

Turunc, Tuba ^{[1
]}

Erkan, Alper Nabi ^{[2
]}

Alkan, Ozlem ^{[3
]}

Aliskan, Hikmet Eda ^{[4
]}

Colakoglu, Sule ^{[4
]}

Arslan, Hande ^{[1
]}

机构：

[1] Baskent Univ, Tip Fak, Infeksiyon Hastaliklari & Klin Mikrobiyoloji Anab, Ankara, Turkey

[2] Baskent Univ, Tip Fak, Kulak Burun & Bogaz Hastaliklari Anabilim Dali, Ankara, Turkey

[3] Baskent Univ, Tip Fak, Radyol Anabilim Dali, Ankara, Turkey

[4] Baskent Univ, Tip Fak, Mikrobiyol & Klin Mikrobiyol Anabilim Dali, Ankara, Turkey

来源：

KLIMIK JOURNAL | 2010年 / 23卷 / 03期

关键词：

Mucormycosis; posaconazole; salvage therapy;

D O I：

10.5152/kd.2010.34

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mucormycosis is an angioinvasive disease with an acute onset, fatal and aggressive course, which is commonly seen in immunosuppressed patients. In this case report, a 55-year-old diabetic man with rhinocerebral mucormycosis who was admitted with fever, headache and periorbital cellulitis, was presented. Although liposomal amphotericin B was given for as long as 90 days after an endoscopic sinus surgery, the clinical picture showed progression without a clinical response. Therefore, oral posaconazole was prescribed. Posaconazole therapy enabled not only his survival but also his follow up on an outpatient basis. Posaconazole was prescribed during one year without any severe side effect and was well tolerated. As a result, posaconazole is a safe drug that may be used as salvage therapy in patients with mucormycosis refractory to liposomal amphotericin B treatment.

引用

页码：130 / 133

页数：4

共 22 条

[1] Mucormycosis:: an emerging disease? [J].

Bouza, E. ;

Munoz, P. ;

Guinea, J. .

CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :7-23

[2] Zygomycosis: the re-emerging fungal infection [J].

Chayakulkeeree, M. ;

Ghannoum, M. A. ;

Perfect, J. R. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2006, 25 (04) :215-229

[3] Improved outcome of zygomycosis in patients with hematological diseases? [J].

Gleissner, B ;

Schilling, A ;

Anagnostopolous, I ;

Siehl, I ;

Thiel, E .

LEUKEMIA & LYMPHOMA, 2004, 45 (07) :1351-1360

[4] Preface - Fungal infections, - Part I - Recent advances in diagnosis, treatment, and prevention of opportunistic mycoses [J].

Walsh, TJ ;

Rex, JH .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (04) :IX-X

[5] Posaconazole as salvage therapy for zygomycosis [J].

Greenberg, RN ;

Mullane, K ;

van Burik, JAH ;

Raad, I ;

Abzug, MJ ;

Anstead, G ;

Herbrecht, R ;

Langston, A ;

Marr, KA ;

Schiller, G ;

Schuster, M ;

Wingard, JR ;

Gonzalez, CE ;

Revankar, SG ;

Corcoran, G ;

Kryscio, RJ ;

Hare, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :126-133

[6] Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system [J].

Groll, AH ;

Giri, N ;

Petraitis, V ;

Petraitiene, R ;

Candelario, M ;

Bacher, JS ;

Piscitelli, SC ;

Walsh, TJ .

JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (01) :274-282

[7] Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections [J].

Herbrecht, R .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (06) :612-624

[8] Comparison of lipid amphotericin B preparations in treating murine zygomycosis [J].

Ibrahim, Ashraf S. ;

Gebremariam, Teclegiorgis ;

Husseiny, Mohamed I. ;

Stevens, David A. ;

Fu, Yue ;

Edwards, John E., Jr. ;

Spellberg, Brad .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1573-1576

[9]

Khor Boon-Siang, 2003, Journal of Microbiology Immunology and Infection, V36, P266

[10]

Nithyanandam Suneetha, 2003, Indian Journal of Ophthalmology, V51, P231

← 1 2 3 →